09:59 AM EST - Oncolytics Biotech Inc. : ,currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, today announced its collaboration in which PrECOG will run the BRACELET-1 (PrE0113) study. The principal investigator will be Kathy Miller, MD, Ballve-Lantero Professor of Oncology at Indiana University School of Medicine and Associate Director of Clinical Research at Indiana University Melvin and Bren Simon Cancer Center, and PrECOG member. The study will take place in 15 centres in the United States and will evaluate the ability of pelareorep to make tumors immunologically visible to checkpoint inhibitors. Oncolytics Biotech Inc.
shares T.ONC are trading down $0.01 at $0.61.
